Journal: medRxiv

Article Title: In Vivo Blood Kinetics and Transcript Integrity of Three mRNA–Lipid Nanoparticle Vaccines in Humans

doi: 10.64898/2026.03.13.26348310

Figure Lengend Snippet: A) Three cohort of human subjects were recruited who received either Moderna, Pfizer, or mRNA-RBD vaccination. B) Serial blood samples were collected before and after vaccination and analyzed by ddPCR, mass spectrometry and ELISA to quantify vaccine mRNA, ionizable lipid, and antibody response (anti-PEG and anti-spike), respectively.

Article Snippet: Pre-existing anti-PEG IgM was detectable in 28/29 (97%), 7/12 (58%), and 11/26 (42%) participants in the Moderna, Pfizer, and mRNA–RBD cohorts, respectively ( ).

Techniques: Mass Spectrometry, Enzyme-linked Immunosorbent Assay

Journal: medRxiv

Article Title: In Vivo Blood Kinetics and Transcript Integrity of Three mRNA–Lipid Nanoparticle Vaccines in Humans

doi: 10.64898/2026.03.13.26348310

Figure Lengend Snippet: Comparison of anti-PEG antibody levels in human blood before and after Moderna, Pfizer, or mRNA-RBD vaccination. (A,B) Comparison of plasma anti-PEG IgG and IgM endpoint titers before vaccination (Pre-Vax) and after vaccination (Post-Vax) for the three vaccine types. (C,D) Cross-comparison of fold changes (Post-Vax/Pre-Vax) in anti-PEG IgG and IgM endpoint titers among the three vaccine types. In (C,D), each dot represents one participant, and the horizontal line indicates the mean. Statistical analysis was performed using the nonparametric Wilcoxon matched-pairs signed rank test in (A,B) and the nonparametric Kruskal–Wallis test with Dunn’s multiple comparisons in (C,D).

Article Snippet: Pre-existing anti-PEG IgM was detectable in 28/29 (97%), 7/12 (58%), and 11/26 (42%) participants in the Moderna, Pfizer, and mRNA–RBD cohorts, respectively ( ).

Techniques: Comparison, Clinical Proteomics

Journal: medRxiv

Article Title: In Vivo Blood Kinetics and Transcript Integrity of Three mRNA–Lipid Nanoparticle Vaccines in Humans

doi: 10.64898/2026.03.13.26348310

Figure Lengend Snippet: A) Three cohort of human subjects were recruited who received either Moderna, Pfizer, or mRNA-RBD vaccination. B) Serial blood samples were collected before and after vaccination and analyzed by ddPCR, mass spectrometry and ELISA to quantify vaccine mRNA, ionizable lipid, and antibody response (anti-PEG and anti-spike), respectively.

Article Snippet: In the Moderna cohort, both anti-PEG IgG and IgM were boosted at day 28, with mean fold changes of 2.0 (range 1–6.7) and 5.9 (range 1–33.6), respectively ( ).

Techniques: Mass Spectrometry, Enzyme-linked Immunosorbent Assay

Journal: medRxiv

Article Title: In Vivo Blood Kinetics and Transcript Integrity of Three mRNA–Lipid Nanoparticle Vaccines in Humans

doi: 10.64898/2026.03.13.26348310

Figure Lengend Snippet: Comparison of anti-PEG antibody levels in human blood before and after Moderna, Pfizer, or mRNA-RBD vaccination. (A,B) Comparison of plasma anti-PEG IgG and IgM endpoint titers before vaccination (Pre-Vax) and after vaccination (Post-Vax) for the three vaccine types. (C,D) Cross-comparison of fold changes (Post-Vax/Pre-Vax) in anti-PEG IgG and IgM endpoint titers among the three vaccine types. In (C,D), each dot represents one participant, and the horizontal line indicates the mean. Statistical analysis was performed using the nonparametric Wilcoxon matched-pairs signed rank test in (A,B) and the nonparametric Kruskal–Wallis test with Dunn’s multiple comparisons in (C,D).

Article Snippet: In the Moderna cohort, both anti-PEG IgG and IgM were boosted at day 28, with mean fold changes of 2.0 (range 1–6.7) and 5.9 (range 1–33.6), respectively ( ).

Techniques: Comparison, Clinical Proteomics

Journal: medRxiv

Article Title: In Vivo Blood Kinetics and Transcript Integrity of Three mRNA–Lipid Nanoparticle Vaccines in Humans

doi: 10.64898/2026.03.13.26348310

Figure Lengend Snippet: A) Three cohort of human subjects were recruited who received either Moderna, Pfizer, or mRNA-RBD vaccination. B) Serial blood samples were collected before and after vaccination and analyzed by ddPCR, mass spectrometry and ELISA to quantify vaccine mRNA, ionizable lipid, and antibody response (anti-PEG and anti-spike), respectively.

Article Snippet: Pre-existing anti-PEG IgM was detectable in 28/29 (97%), 7/12 (58%), and 11/26 (42%) participants in the Moderna, Pfizer, and mRNA–RBD cohorts, respectively ( ).

Techniques: Mass Spectrometry, Enzyme-linked Immunosorbent Assay

Journal: medRxiv

Article Title: In Vivo Blood Kinetics and Transcript Integrity of Three mRNA–Lipid Nanoparticle Vaccines in Humans

doi: 10.64898/2026.03.13.26348310

Figure Lengend Snippet: Comparison of anti-PEG antibody levels in human blood before and after Moderna, Pfizer, or mRNA-RBD vaccination. (A,B) Comparison of plasma anti-PEG IgG and IgM endpoint titers before vaccination (Pre-Vax) and after vaccination (Post-Vax) for the three vaccine types. (C,D) Cross-comparison of fold changes (Post-Vax/Pre-Vax) in anti-PEG IgG and IgM endpoint titers among the three vaccine types. In (C,D), each dot represents one participant, and the horizontal line indicates the mean. Statistical analysis was performed using the nonparametric Wilcoxon matched-pairs signed rank test in (A,B) and the nonparametric Kruskal–Wallis test with Dunn’s multiple comparisons in (C,D).

Article Snippet: Pre-existing anti-PEG IgM was detectable in 28/29 (97%), 7/12 (58%), and 11/26 (42%) participants in the Moderna, Pfizer, and mRNA–RBD cohorts, respectively ( ).

Techniques: Comparison, Clinical Proteomics